Followers | 124 |
Posts | 12564 |
Boards Moderated | 0 |
Alias Born | 05/07/2012 |
Saturday, December 20, 2014 11:13:47 PM
FOR IMMEDIATE RELEASE
October 14, 2014: A six-month investigation by Project CBD has revealed potentially serious quality control issues in products marketed by Medical Marijuana Inc, (MJNA) and questionable financial dealings between MJNA and its affiliates and subsidiaries.
Highlights from the Special Report written by Aaron Miguel Cantú for Project CBD:
1.Lab tests commissioned by Project CBD reveal significant levels of toxic solvents in samples of Real Scientific Hemp Oil (RSHO) Gold, which is marketed by HempMeds, a wholly owned subsidiary of MJNA. These samples were submitted to Project CBD by people who say that they or their children became ill, in some cases, violently ill, after they ingested RSHO Gold.
2.Promotional campaigns by MJNA and its subsidiaries have aggressively targeted children with serious disabilities in an effort to profit from CBD’s growing reputation as a miracle compound. (A remedy of last resort for children with catastrophic seizure disorders, CBD-rich oil from other sources has proven effective in some cases of treatment-resistant epilepsy.)
3.Kannaway, another MJNA subsidiary, is engaging in business practices that may qualify it as a pyramid scheme based on guidelines published by the Federal Trade Commission, Bureau of Consumer Protection, and Division of Consumer and Business Education.
4.Discrepancies between MJNA business results and its press strategy have caused industry analysts to raise questions about a “pump and dump” stock scheme and potential financial fraud.
5.MJNA asserts that its CBD-infused “hemp oil” is legal in all 50 states despite DEA and FDA assertions that cannabidiol in any form (hemp or plant based) is still a schedule I substance, and evidence that the THC content sometimes exceeds federal limits.
http://www.projectcbd.org/project-cbd-issues-a-special-report-on-medical-marijuana-inc-hempmeds-and-kannaway/
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM